Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
13/11/26	SEK 0.3195	0.00%	2,774,204
11/11/26	SEK 0.3195	-5.33%	2,057,969
10/11/26	SEK 0.3375	+2.12%	965,636
09/11/26	SEK 0.3305	-3.92%	1,491,659
06/11/26	SEK 0.3440	+1.18%	1,303,147

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzinova AB

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alzinova AB

Company calendar

Market Closed - Nasdaq Stockholm 04:00:00 13/11/26 am AEDT			5-day change	1st Jan Change
0.3195 ^SEK	0.00%		-6.03%	-61.46%

06:36pm	Alzinova narrows loss	FW
06/11	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW

Market Cap	101M 10.08M 9.11M 8.41M 7.62M 14.37M 947M 14.8M 40.13M 507M 37.83M 37.02M 1.61B	P/E 2026 *	-2.28x	P/E 2027 *	-1.18x
Enterprise Value	91.98M 9.18M 8.3M 7.66M 6.94M 13.09M 863M 13.48M 36.55M 461M 34.46M 33.72M 1.47B	EV / Sales 2026 *	2.93x	EV / Sales 2027 *	-
Free-Float	82.68%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

06:36pm	Alzinova narrows loss	FW
06/11	16 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange	FW
03/11	Alzinova Seeks US Ethical Approval for Phase 2a Alzheimer's Vaccine Study	MT
03/11	Alzinova submits ethics application for Phase 2a study in the US	FW
03/11	Alzinova Moves Closer To Phase 2a Initiation With US Ethics Submission	CI
02/11	17 stocks have hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
02/11	Alzinova submits updated documentation to FDA ahead of Phase 2a study	FW
21/10	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
21/10	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW
21/10	Alzinova AB Finalises Selection Of Seven US Clinical Sites As ADVANCE Phase 2a Study Moves Toward First Participant Enrolment	CI
20/10	Alzinova carries out directed issue worth SEK 3.6m to Mangold	FW
15/10	Calendar Thursday October 15	FW
09/10	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/10	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
07/10	RX Securities reiterates Buy on Alzinova, cuts fair value to SEK 2.50	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW

06:35pm	Alzinova : publishes interim report for the period January - September 2026	PU
02/11	Alzinova : takes further step toward Phase 2a ADVANCE study with submitted FDA amendment for ALZ-101	PU
09/10	Alzinova: Rights issue subscribed to 86.2%	AQ
09/10	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day	AQ
08/10	Alzinova: Rights issue completed	AQ

1 week	-6.03%
Current month	-9.87%
1 month	-33.85%
3 months	-65.35%
6 months	-21.11%
Current year	-61.46%

1 week	0.3	0.35
1 month	0.3	0.49
Current year	0.3	1.61
1 year	0.3	2.07
3 years	0.3	4.62
5 years	0.3	7.74
10 years	0.3	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Anders Waas BRD	Director/Board Member	69	01/01/2018
Per-Göran Gillberg BRD	Director/Board Member	70	01/01/2020
Julian Aleksov CHM	Chairman	61	01/01/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	0.00%	-6.03%	-73.81%	-87.04%	10.12M
WUXI APPTEC CO., LTD.	+1.10%	+1.03%	+62.53%	+70.47%	67.53B
ARGENX SE	+1.28%	+8.71%	+13.96%	+92.70%	60.74B
LONZA GROUP AG	+0.36%	-0.95%	+20.09%	+98.45%	55.66B
BEONE MEDICINES AG	-0.06%	+8.74%	+11.56%	+111.77%	47.97B
IQVIA HOLDINGS INC.	-1.53%	+2.26%	+22.63%	+39.86%	45.24B
REVOLUTION MEDICINES, INC.	-1.82%	+0.12%	+170.17%	+805.11%	39.08B
CELLTRION, INC.	+1.21%	+4.75%	+27.30%	+52.81%	35.34B
GENMAB A/S	-0.87%	-2.89%	+79.60%	+56.33%	33.45B
INSMED INCORPORATED	-1.89%	+9.03%	-39.00%	+396.15%	26.49B
Average	-0.20%	+1.89%	+29.50%	+163.66%	41B
Weighted average by Cap.	+0.01%	+2.88%	+41.34%	+167.05%

	2026 *	2027 *
Net sales	31.35M 3.13M 2.83M 2.61M 2.36M 4.46M 294M 4.59M 12.46M 157M 11.74M 11.49M 501M	-
Net income	1.55M 155K 140K 129K 117K 221K 14.54M 227K 616K 7.78M 581K 568K 24.75M	-84M -8.38M -7.58M -7M -6.33M -11.95M -788M -12.31M -33.38M -421M -31.47M -30.8M -1.34B
Net Debt	-9M -898K -812K -750K -679K -1.28M -84.45M -1.32M -3.58M -45.15M -3.37M -3.3M -144M	-4M -399K -361K -333K -302K -569K -37.53M -586K -1.59M -20.06M -1.5M -1.47M -63.87M